HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31

Cellyan Biotechnology Co., Ltd

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Aug 7, 2026

$0.11+0.00 (+1.81%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Cellyan Biotechnology has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Cellyan Biotechnology filed with the SEC

Sep 9, 2026, 8:55 PM ET
FORM OF PROXY STATEMENT AND NOTICE OF EXTRAORDINARY GENERAL MEETING
EX-99.1 to Form 6-K
Sep 9, 2026, 8:55 PM ET
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Jul 16, 2026, 4:31 PM ET
PRESS RELEASE - CELLYAN BIOTECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE OF ADDITIONAL COMPLIANCE GRACE PERIOD
EX-99.1 to Form 6-K
Mar 18, 2026, 4:30 PM ET
Consolidated Financial Statements for the Six Months Ended September 30, 2025 and 2024 (unaudited)
EX-99.1 to Form 6-K
Mar 18, 2026, 4:30 PM ET
OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2025 AND FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
EX-99.2 to Form 6-K
Jan 16, 2026, 4:29 PM ET
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price
EX-99.1 to Form 6-K
Dec 17, 2025, 4:30 PM ET
PRESS RELEASE TITLED "HONG KONG PHARMA DIGITAL ANNOUNCED RESULTS OF 2025 ANNUAL MEETING OF STOCKHOLDERS", DATED DECEMBER 17, 2025
EX-99.1 to Form 6-K
Nov 24, 2025, 8:58 AM ET
PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS, DATED NOVEMBER [14], 2025
EX-99.1 to Form 6-K
Nov 24, 2025, 8:58 AM ET
FORM OF PROXY CARD OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
Nov 24, 2025, 8:58 AM ET
HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED 2025 EQUITY INCENTIVE PLAN
EX-99.3 to Form 6-K
Oct 6, 2025, 6:47 PM ET
EMPLOYMENT AGREEMENT, DATED OCTOBER 6, 2025 BY AND BETWEEN THE COMPANY AND CHENYU LIANG
EX-99.1 to Form 6-K
Oct 6, 2025, 6:47 PM ET
EMPLOYMENT AGREEMENT, DATED OCTOBER 6, 2025 BY AND BETWEEN THE COMPANY AND SHU LIU
EX-99.2 to Form 6-K
Oct 6, 2025, 6:47 PM ET
EMPLOYMENT AGREEMENT, DATED OCTOBER 6, 2025 BY AND BETWEEN THE COMPANY AND ZIFENG WANG
EX-99.3 to Form 6-K
Mar 28, 2025, 4:30 PM ET
UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2024 AND FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
EX-99.1 to Form 6-K
Mar 28, 2025, 4:30 PM ET
PRESS RELEASE DATED MARCH 28, 2025
EX-99.2 to Form 6-K
Jan 17, 2025, 4:00 PM ET
PRESS RELEASE DATED JANUARY 14, 2025, ANNOUNCING THE PRICING OF THE COMPANY'S IPO
EX-99.1 to Form 6-K
Jan 17, 2025, 4:00 PM ET
PRESS RELEASE DATED JANUARY 16, 2025, ANNOUNCING THE CLOSING OF THE COMPANY'S IPO
EX-99.2 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Cellyan Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HKPD.

Revenue growth-33.9% · median -38.6%

Gross margin10.3% · median 10.3%

Operating margin-17.8% · median -100.8%

Net margin-8.5% · median -159.7%

Company	Revenue	Growth
COSM	$73.73M	+33.8%
HKPD	$13.43M	-33.9%
MEDS	$8.02M	-78.2%
STEK	$2.40M	-38.6%
BHATF	–	–
GVH	–	–

Company

Exchange: Nasdaq
Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Fiscal year ends: March 31
Employees: 2
Auditor: ONESTOP ASSURANCE PAC
SEC CIK: 2007702

Advertisement
300 × 250